GNS in combination with amikacin is a potential new treatment against carbapenem-resistant K. pneumoniae strains, joining many other promising new nanoparticle-based strategies to fight this kind of infections, such as silver nanoparticles [70], imipenem-loaded poly-ε-caprolactone and polylactide-co-glycolide nanocapsules [71], or bovine serum albumin nanoparticles reinforced K. pneumoniae outer-membrane vesicles [72]; peptides, e.g., Komodo-dragon cathelicidin-inspired peptides [73]; or based on polycationic oligoethyleneimine [74]. The gene discussed is ALB; the disease is infection.